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Purpose: Erlotinib is a novel therapeutic agent for cancer treatment. This study was performed to investigate the
role of c-MET-PI3K-AKT pathway in the regulation of erlotinib-induced radiosensitization.
Methods: A973 lung adenocarcinoma cells treated with 6 Gy of radiation were incubated in the presence of
erlotinib. The apoptotic rate after 24 hours, the colony-formating rate after 14 days, and changes in the c-MET
expression levels after 14 days of irradiation were examined. Surviving fractions in different treatment groups (blank
control, radiation alone, erlotinib alone, anti-c-MET monoclonal antibody alone, combined erlotinib and radiation,
and combined erlotinib and radiation with anti-c-MET monoclonal antibody groups) were determined, the survival
curves were plotted, and the sensitizer enhancement ratio was calculated using colony formation assays. Expressions of
c-MET, p-c-MET, PI3K, AKT, and p-AKT in cells in different treatment groups were examined by Western blot analysis.
Results: The apoptotic rate in the combined erlotinib and radiation group was higher than those in single
treatment groups; however, the colony-forming rate remained approximately 2.04 ± 1.02%. The expression of
c-MET in colony-forming cells in the combined group significantly increased, and the blockade of c-MET activity
significantly enhanced the radiosensitizing effect of erlotinib. The expression of c-Met, p-c-MET, PI3K, AKT, and
p-AKT among colony-forming cells significantly decreased upon the inhibition of c-MET.
Conclusions: Upregulated activity of the c-MET-PI3K-AKT pathway was found to be important for cell survival
under combined the treatment with erlotinib and radiation. The blockade of the c-MET-PI3K-AKT signaling pathway
enhanced the radiosensitizing effect of erlotinib.
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A number of previous studies have demonstrated a clear
radiosensitizing effect of erlotinib treatment [1-3]. However,
the combined treatment with erlotinib and radiation
sometimes exhibits poor antitumor effects [4]. Our
previous report suggested that the extent of antitumor
effects of the combined erlotinib and radiation treat-
ment may be related to the PI3K pathway [5], although* Correspondence: hongqingzhuang@163.com
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unless otherwise stated.the underlying mechanism remains unclear. Therefore, the
study of signaling pathways related to erlotinib-induced
radiosensitization, understanding the survival mechanisms
of tumor cells under the combined treatment with erloti-
nib and radiation, and further exploration of methods to
enhance the radiosensitizing effect of erlotinib may have
potential clinical significance.Materials and method
Reagents and cell culture
RPMI-1640 culture medium was obtained from Gibco
(USA, Grand Island), and fetal bovine serum was ob-
tained from Hangzhou Sijiqing Biological Engineering
Materials Co., Ltd. Monoclonal antibodies targeting c-MET,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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AKT were purchased from Santa Cruz Biotechnology, Inc.
(USA, Dallas, Texas). RNase A and propidium iodide (PI)
were obtained from Sigma (USA, St. Louis, MO). The CO2
incubator used for cell culture was purchased from Heraeus
(Germany, Frankfurt), and the high-speed refrigerated
centrifuge was also obtained from Heraeus. The flow cyt-
ometer was from Beckman Coulter, Inc. (USA, California).
The A973 lung adenocarcinoma cell line was used in this
study. A973 cells expressed high levels of epidermal
growth factor receptor (EGFR) and phospho-EGFR, as re-
ported previously [5-7]. Cells were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum,
100 IU/ml penicillin, and 100 IU/ml streptomycin in a
37°C incubator with an atmosphere of 5% CO2. Cells in
the exponential growth phase were irradiated.
Colony formation assay
Colony-forming rates of the tumor cells were determined
using the colony formation assay. The experiments on
erlotinib-induced radiosensitization included the following
treatment groups: blank control group, radiation alone
group, erlotinib alone group, anti-c-MET monoclonal
antibody alone group, combined erlotinib and radi-
ation group, and combined erlotinib and radiation with
anti-c-MET monoclonal antibody group. Cells in the
exponential growth phase were trypsinized, counted,
diluted, and seeded onto 35-ml flasks. The number of
cells seeded onto the flasks was adjusted according to
the radiation dose (500, 1000, 2000, 4000, 6000, 8000,
and 10000 cells were seeded in 0, 1, 2, 4, 6, 8, and
10 Gy groups, respectively). The concentrations of
erlotinib and anti-c-MET monoclonal antibody used
were 20 nM. and 10 nM, respectively. A radiation dose
of 2 Gy/min was selected, and cells were exposed to 0,
1, 2, 4, 6, 8, or 10 Gy of radiation after the attachment
of cells on the plastic at 37°C, 5% CO2, and constant
humidity. After 14 days of cell seeding, the culture dishes
were collected, and the culture medium was discarded.
Cells were fixed and subjected to Giemsa staining. The
number of colonies containing more than 50 cells was
counted, and the cell survival fraction (SF) was calculated.
The experiments were confirmed three times, and each
treatment group contained three parallel samples. The
single-hit, multitarget model was used to fit the cell
survival curves [8-10].
Flow cytometry
Cell apoptosis and the expression of c-MET were exam-
ined by flow cytometry. Experiments included the follow-
ing treatment groups: blank control group, radiation alone
group, erlotinib alone group, and combined erlotinib and
radiation group. The concentrations of erlotinib and the
anti-c-MET monoclonal antibody were the same as thoselisted in the preceding section. All irradiated groups were
given a dose of 6 Gy. Colony-forming cells from different
treatment groups were collected, and the apoptotic
rates and expression of c-MET were determined by
flow cytometry. Apoptosis was measured experimen-
tally as follows: first, cells were trypsinized, and 5 × 105
cells were collected. After adding 1 ml of cold phos-
phate buffered saline (PBS), the cells were centrifuged
at 1000 rpm for 10 min at 4°C. The cells were then
washed with PBS, centrifuged twice under the above
conditions, and resuspended in 200 μl of binding buffer.
Ten microliters of Annexin-FITC was added to the cell
suspension and mixed well. The cell mixture was incu-
bated at room temperature in the dark for 15 min, and
then an additional 300 μl of binding buffer was added.
Finally, the cells were analyzed by flow cytometry after
adding 5 μl of PI. To detect the expression of c-MET,
the cells were incubated with the PE-coupled mouse
anti-human c-MET monoclonal antibody, washed, incu-
bated with the FITC-coupled rabbit anti-mouse antibody,
washed, and then subjected to flow cytometry analysis
[11,12].
Western blotting
The expressions of c-MET, p-c-MET, PI3K, AKT, and
p-AKT in the blank control group, the combined erlo-
tinib and radiation group, and the combined erlotinib
and radiation with anti-c-MET monoclonal antibody
group were examined using Western blotting,. The
concentrations of erlotinib and the anti-c-MET monoclo-
nal antibody were the same as those described above. Cells
were irradiated at a dose of 6 Gy. The experimental pro-
cedures were performed as follows: 14 days after treat-
ment, the cells were trypsinized and collected. The total
protein was extracted from the cells, and the protein
concentration was determined by Coomassie brilliant
blue staining. The proteins were separated by polyacryl-
amide gel electrophoresis and transferred onto polyvi-
nylidene difluoride membranes. The membranes were
then probed with primary antibodies, washed, incubated
with horseradish peroxidase–conjugated secondary anti-
bodies, and washed again. Finally, protein signals were
visualized [13,14].
Statistical analysis
Origin7.5 software was used to fit the cell survival curves.
Data were presented as the mean ± standard deviation and
were analyzed using SPSS17.0 software. The analysis of
variance (ANOVA) tables were used to perform com-
parisons between multiple groups. P values less than 0.05
were considered statistically significant.
Patient consent
The study was not related with patients.
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Apoptosis and colony formation under the combined
treatment of erlotinib and 6 Gy of radiation
Our results showed that the apoptotic rates of cells in
the blank control group, erlotinib alone group, radiation
alone group, and combined erlotinib and radiation group
after 24 hours of treatment were 2.43 ± 1.03%, 11.26 ±
2.14%, 23.45 ± 4.35%, and 47.68 ± 6.73%, respectively.
The apoptotic rate in the combined treatment group
was significantly higher than those in the other groups
(ANOVA analysis, P < 0.05). The number of colonies
was counted after 14 days of treatment, and the colony-
forming rates of cells in the blank control group, erlotinib
alone group, radiation alone group, and combined erlotinib
and radiation group were 71.45 ± 4.64%, 43.56 ± 3.38%,
15.6 ± 2.26%, and 2.04 ± 1.02%, respectively. Although the
colony-forming rate in the combined treatment group was
the lowest (Figure 1, ANOVA analysis, P < 0.05). These re-
sults showed that erlotinib exhibited a clear radiosensitiz-
ing effect. However, a portion of the tumor cells survived
the combined treatment with erlotinib and radiation and
eventually formed colonies.
The expression of c-MET in colony-forming cells after the
combined treatment with erlotinib and radiation
Cells from the blank control group, the erlotinib alone
group, the radiation (6 Gy) alone group, and the combined
erlotinib and radiation group after 14 days of treatment
were collected, and the results of the flow cytometry ana-
lysis showed that the expression rates of c-MET in these
groups were 12.25 ± 2.17%, 23.36 ± 3.16%, 27.45 ± 3.79%,
and 75.35 ± 6.33%, respectively. Compared to other groups,
the expression rate of c-MET in the combined treatment
group significantly increased (Figure 2, ANOVA analysis,
P < 0.05). These results showed that both radiation and er-
lotinib were contributing factors to the increased c-MET
expression. Moreover, the combination of radiation andFigure 1 Apoptosis and colony formation under the combined treatm
apoptotic rate was 2.43 ± 1.03%; the colony formation rate was 71.45 ± 4.64
colony formation rate was 43.56 ± 3.38%. (C) Radiation group: the apoptoti
(D) combined treatment with erlotinib and radiation group: the apoptoticerlotinib had a synergistic effect on the upregulation of
c-MET expression.
The inhibition of c-MET activity further enhances the
radiosensitizing effect of erlotinib
The survival curves showed that erlotinib exhibited a
clear radiosensitizing effect. Compared to the combined
erlotinib and radiation group, the inhibition of the c-MET
signaling pathway in these cells using a monoclonal anti-
body further decreased the SF and enhanced the radiosen-
sitizing effect (ANOVA analysis, P < 0.05, Figure 3). The
D0, N, and Dq values for the radiation alone group were
2.51, 2.93, and 1.17, respectively, and for the combined
erlotinib and radiation group were 1.54, 1.62, and 0.32,
respectively; the sensitizer enhancement ratio was 1.63.
The D0, N, and Dq values for the combined erlotinib and
radiation with anti-c-MET monoclonal antibody treat-
ment group were 1.01, 1.17, and 0.07, respectively, and the
sensitizer enhancement ratio was 2.49. Therefore, the ele-
vated c-MET expression likely acted as a survival factor
for the tumor cells treated with a combination of erlotinib
and radiation, and the blockade of c-MET signaling signifi-
cantly enhanced the tumor cytotoxicity effects.
Changes in protein expression related to the
c-MET-PI3K-AKT pathway in colony-forming cells
from the combined erlotinib and radiation group
before and after c-MET inhibition
To study the possible survival mechanism utilized by
colony-forming cells, cells from the blank control
group, the combined erlotinib and radiation group, and
the combined erlotinib and radiation with anti-c-MET
monoclonal antibody group were collected after 14 days
of treatment, and the expression of c-MET, phosphory-
lated c-MET, PI3K, AKT, and phosphorylated AKT was
examined. The results showed that the expression of these
proteins significantly increased after 14 days of treatment.ent of erlotinib(20 nM) and 6 Gy radiation. (A) Control group: the
%. (B) Erlotinib group: the apoptotic rate was 11.26 ± 2.14%; the
c rate was 23.45 ± 4.35%; the colony formation rate was 15.6 ± 2.26%.
rate was 47.68 ± 6.73%; the colony formation rate was 2.04 ± 1.02%.
Figure 2 The expression of c-MET in colony-forming cells after combined treatment with erlotinib (20 nM) and radiation (6Gy). M1: the
cell of c-MET non-expression. M2: the cell of c-MET expression. The expressions of c-MET (M2) were as follows: (A) Control group: 12.25 ± 2.17%.
(B) Erlotinib group: 23.36 ± 3.16%. (C) Radiation group: 27.45 ± 3.79%. (D) combined treatment with erlotinib and radiation group: 75.35 ± 6.33%.
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clonal antibody, the expression of these proteins signifi-
cantly decreased (Figure 4). Moreover, the changes in
protein expression observed before and after inhibiting
the c-MET-PI3K-AKT pathway using the anti-c-MET
monoclonal antibody further indicated that the activation
of the c-MET-PI3K-AKT pathway was an important
mechanism for A973 cell survival and colony formation
after the combined treatment with erlotinib and radiation.
Therefore, blockade of this pathway may represent a novelFigure 3 Inhibition of c-MET activity further enhances the
radiosensitizing effect of erlotinib. Compared to the combined
erlotinib(20NM) and radiation group, inhibition of the c-MET signaling
pathway using a monoclonal antibody(10 nM) further decreased the
survival fraction and enhanced the radiosensitizing effect (ANOVA
analysis, P < 0.05) (A) Radiation group. (B) Combined erlotinib and
radiation group. (C) Combined erlotinib and radiation with
anti-c-MET monoclonal antibody treatment group.
Figure 4 Protein expression in colony-forming cells from the
combined erlotinib and radiation group before and after c-MET
inhibition. The radiation dose was 6Gy. Erlotinib was used at a
concentration of 20 nM. The anti-c-MET monoclonal antibody was
applied at a concentration of 10 nM too. (A) Control group. (B)
Combined erlotinib and radiation group. (C) Combined erlotinib and
radiation with anti-c-MET monoclonal antibody treatment group.
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erlotinib.
Discussion
The results of the present study indicated that the acti-
vation of the c-MET-PI3K-AKT pathway served as an
important survival mechanism for cells that received
the combined treatment with erlotinib and radiation.
However, blockade of the c-MET-PI3K-AKT pathway
could further enhance the radiosensitizing effect of
erlotinib.
Both erlotinib and radiation play important roles in
activating the c-MET-PI3K-AKT pathway, which is one
of the main causes of acquired resistance to erlotinib.
After erlotinib treatment, the PI3K signaling pathway is
significantly upregulated in tumor cells. Consequently,
downstream pathways and nuclear gene expression are
activated, resulting in tumor cell survival and proliferation
[15,16]. In addition, many studies have shown that
radiation stimulates the PI3K pathway [17-20], leading
to radiation resistance in tumor cells. Under the com-
bined action of erlotinib and radiation, the likelihood
of c-MET-PI3K-AKT pathway activation significantly
increases. Based on these findings, we selected c-MET-
PI3K-AKT pathway to evaluate in our research. The
mechanism by which the activated c-MET-PI3K-AKT
pathway promotes tumor cell survival involves cross-talk
between cell signaling pathways [21-24]. Normally, the
EGFR/MAPK (mitogen-activated protein kinase) pathway
is one of the major pathways driving tumor cell prolifera-
tion, whereas the activity of the PI3K pathway decreases
due to the function of phosphatase and tensin homolog
(PTEN). Upon erlotinib treatment, the MAPK pathway is
inhibited and the expression of PTEN is downregulated,
resulting in the decreased inhibition of the PI3K pathway
[25,26]. Owing to the cross-communication between these
pathways, the PI3K pathway is stimulated. Similarly, radi-
ation further enhances the activation of the PI3K pathway.
As a result, the activity of the PI3K pathway increases sig-
nificantly, which maintains cell survival and proliferation
[27,28].
The results of the present study support those of pre-
vious studies mentioned in the preceding paragraph,
because in the present study erlotinib exhibited a clear
radiosensitizing effect. However, many cells survived
under the combined effect of radiation and erlotinib.
The survival of such cells may be because both radiation
and erlotinib can promote the expression of c-MET, which
subsequently activates downstream pathways and affects
their cytotoxic effects. Our finding that the inhibition of
c-MET with a monoclonal antibody decreased the SF of
tumor cells and downregulated the c-MET-PI3K-AKT
pathway activity further confirmed the mechanism of
tumor cell survival, and these results may provide a newapproach to further enhance the cytotoxic effects of
combined therapy with erlotinib and radiation in tumor
cells (Figure 3).
Previous studies have mainly focused on the molecular
mechanism of erlotinib-induced radiosensitization and
cytotoxicity [2,3,29], and few have studied the survival
mechanism of tumor cells given the combined treatment
with erlotinib and radiation. Furthermore, studies exploring
the connection between erlotinib-induced radiosensitiza-
tion and the related signaling pathways are even rarer
[30,31]. However, our present study sought to address
these shortcomings, and we evaluated the c-MET-PI3K-
AKT pathway to study protein expression changes follow-
ing the combined treatment with radiation and erlotinib,
as well as the regulatory effects of blocking of this pathway
on erlotinib-induced radiosensitization. Furthermore, the
current study preliminarily explored the survival mechan-
ism of tumor cells receiving the combined treatment with
erlotinib and radiation and provided constructive ideas for
how to enhance the radiosensitizing effect of erlotinib.
Current and future developments
In summary, this study performed constructive investiga-
tions of changes in the activity of the c-MET-PI3K-AKT
pathway under the combined treatment with erlotinib
and radiation and the regulatory effects of blocking the
c-MET-PI3K-AKT pathway on the radiosensitizing effect
of erlotinib. Our findings revealed an important mechan-
ism for cell survival under the combined treatment with
erlotinib and radiation and provided a new experimental
basis for further enhancing the radiosensitizing effect
of erlotinib. Although only in vitro experiments were
performed in this study and many questions remained
to be fully explored, we believe that with further in-depth
basic research, erlotinib-induced radiosensitization will
achieve superior efficacy and possess a broad clinical
application.
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